Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Trading Down 6.2% – Time to Sell?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)’s stock price was down 6.2% on Monday . The stock traded as low as $39.44 and last traded at $39.4220. Approximately 90,020 shares were traded during trading, a decline of 76% from the average daily volume of 369,847 shares. The stock had previously closed at $42.01.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. TD Cowen started coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They issued a “buy” rating and a $60.00 target price for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Citigroup boosted their price target on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Finally, Wells Fargo & Company increased their price target on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research report on Thursday, September 25th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $52.00.

Kiniksa Pharmaceuticals International Trading Down 0.6%

The company has a market cap of $3.22 billion, a price-to-earnings ratio of 94.27 and a beta of 0.04. The stock’s 50 day moving average price is $41.06 and its 200 day moving average price is $36.17.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The firm had revenue of $180.86 million during the quarter, compared to analysts’ expectations of $166.64 million. During the same period last year, the business posted ($0.18) earnings per share. The company’s quarterly revenue was up 61.2% compared to the same quarter last year. On average, equities analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CEO Sanj K. Patel sold 97,390 shares of the firm’s stock in a transaction dated Wednesday, October 22nd. The shares were sold at an average price of $38.83, for a total value of $3,781,653.70. Following the transaction, the chief executive officer owned 111,794 shares of the company’s stock, valued at $4,340,961.02. This trade represents a 46.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider John F. Paolini sold 82,542 shares of the company’s stock in a transaction on Friday, October 31st. The stock was sold at an average price of $37.14, for a total value of $3,065,609.88. Following the transaction, the insider owned 61,324 shares of the company’s stock, valued at approximately $2,277,573.36. The trade was a 57.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 511,057 shares of company stock worth $19,972,512. 53.48% of the stock is currently owned by insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Large investors have recently added to or reduced their stakes in the business. USA Financial Formulas bought a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter worth $32,000. EverSource Wealth Advisors LLC raised its position in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after acquiring an additional 532 shares in the last quarter. Quarry LP bought a new stake in Kiniksa Pharmaceuticals International in the third quarter worth about $44,000. Osaic Holdings Inc. acquired a new stake in Kiniksa Pharmaceuticals International in the 2nd quarter valued at about $31,000. Finally, Farther Finance Advisors LLC boosted its position in shares of Kiniksa Pharmaceuticals International by 582.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,358 shares of the company’s stock valued at $53,000 after purchasing an additional 1,159 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.